Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis

Blood. 2006 Jun 15;107(12):4834-40. doi: 10.1182/blood-2005-08-3076. Epub 2006 Feb 16.

Abstract

T-cell large granular lymphocytic leukemia (T-LGL) is characterized by chronic clonal lymphoproliferation of cytotoxic T lymphocytes (CTLs). Despite exhibiting phenotypic properties of antigen-activated cells, including expression of Fas and FasL, T-LGL cells accumulate and demonstrate resistance to apoptosis. We propose that increased activity of a prosurvival signaling pathway in T-LGL is responsible for attenuated apoptosis in T-LGL. Given the importance of the phosphatidylinositol-3 kinase (PI3K)-AKT pathway in regulating the balance between survival and apoptosis, we analyzed AKT activity in T-LGL cells. Compared with resting CTLs from healthy donors, patients' T-LGL cells showed higher levels of phosphorylated AKT. We demonstrate that phospho-AKT induction is dependent on the upstream activity of a Src family kinase. Since the PI3K-AKT pathway can antagonize the ability of Fas to initiate apoptosis, we hypothesized that inhibition of PI3K would lead to reacquisition of Fas sensitivity in T-LGL. Inhibition of the PI3K-AKT pathway alone led to brisk spontaneous apoptosis of T-LGL. These results suggest that T-LGL pathogenesis is dependent on activity of the PI3K-AKT pathway, without which the leukemic cells will begin to undergo spontaneous apoptosis. We propose that novel therapeutics inhibiting the PI3K-AKT axis may provide effective treatment for T-LGL.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Apoptosis / immunology*
  • Cell Survival / drug effects
  • Cell Survival / immunology
  • Enzyme Activation / drug effects
  • Enzyme Activation / immunology
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Homeostasis / drug effects
  • Homeostasis / immunology
  • Humans
  • Leukemia, T-Cell / drug therapy
  • Leukemia, T-Cell / immunology*
  • Leukemia, T-Cell / pathology
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology*
  • Male
  • Oncogene Protein v-akt / immunology
  • Phosphatidylinositol 3-Kinases / immunology*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Signal Transduction / drug effects
  • Signal Transduction / immunology*
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / pathology
  • fas Receptor / immunology
  • src-Family Kinases / immunology

Substances

  • Enzyme Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • fas Receptor
  • src-Family Kinases
  • Oncogene Protein v-akt